Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CRISPR Therapeutics AG CRSP

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.


NDAQ:CRSP - Post by User

Bullboard Posts
Comment by Pete57on Jun 12, 2018 12:25pm
129 Views
Post# 28160121

RE:Edited cells might cause cancer

RE:Edited cells might cause cancerBut others have doubts about these studies.

https://seekingalpha.com/article/4181056-crispr-therapeutics-cancer-concerns-unjustified-market-reaction

"[...]there are two broad approaches to gene editing - one, replacing a mutated gene, and two, disrupting a mutated gene so it doesn't express a harmful protein. The second is also called gene knock down. Gene disruption, which is the approach taken by "CRISPR Therapeutics' sickle-cell and thalassemia programs as well as Editas Medicine's lead product, targeting a form of blindness, and others in its pipeline," can occur even when p53 is activated. Meaning, this approach does not cause cancer. The same goes for NTLA's transthyretin amyloidosis.
 
The problem only occurs in what is called double stranded breaks or DSBs; that is, when CRISPR tries to replace mutated DNA with healthy DNA. That seems to make p53 go haywire."

So, it seems to be hard to replace a gene vs disrupting it. But I don't understand what you can do by disrupting a gene. It's way over my head. I think in some disease, just disabling a gene would cure the disease but it will not work if the good version of the gene is needed.

Disrupting a gene could be a good possibility to treat cancer (we are far from this) by knocking  down the bad gene mutation that causing cells multiplication.
 
Bullboard Posts